Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last month.

The biotech also closed its San Bruno, Calif. office...